Hypertrophic cardiomyopathy without hypertrophy: an emerging pre-clinical subgroup composed of genetically affected family members.

[1]  Luigi Rega,et al.  Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[2]  B. Maron,et al.  Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. , 2005, Journal of the American College of Cardiology.

[3]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[4]  V. Regitz-Zagrosek,et al.  The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. , 2003, European heart journal.

[5]  N. Cardim,et al.  Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy. , 2002, The American journal of cardiology.

[6]  S. Solomon,et al.  Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy , 2002, Circulation.

[7]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[8]  H Niimura,et al.  Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. , 2001, Journal of the American College of Cardiology.

[9]  M. Quiñones,et al.  Tissue Doppler Imaging Consistently Detects Myocardial Abnormalities in Patients With Hypertrophic Cardiomyopathy and Provides a Novel Means for an Early Diagnosis Before and Independently of Hypertrophy , 2001, Circulation.

[10]  James O. Mudd,et al.  An abnormal Ca2+ response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy , 2000 .

[11]  M. Quiñones,et al.  Tissue Doppler Imaging Consistently Detects Myocardial Contraction and Relaxation Abnormalities, Irrespective of Cardiac Hypertrophy, in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2000, Circulation.

[12]  J. Seidman,et al.  Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. , 1999, Circulation research.

[13]  Dimitrios Georgakopoulos,et al.  The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an α-cardiac myosin heavy chain missense mutation , 1999, Nature Medicine.

[14]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[15]  J. Seidman,et al.  Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[16]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[17]  B. Maron,et al.  Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. , 1989, The American journal of cardiology.

[18]  B. Maron,et al.  Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. , 1986, The New England journal of medicine.

[19]  F. T. ten Cate,et al.  Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. , 2009, JACC. Cardiovascular imaging.

[20]  R. Bonow,et al.  36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes With Cardiovascular Abnormalities , 2005 .

[21]  H. Heidbuchel,et al.  Recommendations for competitive sports participation in athletes with cardiovascular disease , 2005 .

[22]  J. Schmitt,et al.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.

[23]  James O. Mudd,et al.  An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. , 2000, The Journal of clinical investigation.